ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Ranolazine

Also written as “Test formulation (Ranolazine extended-release tablets)”, “Reference formulation (Ranolazine extended-release tablets)” and “Ranolazine 500 mg”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Angina Pectoris · Atrial Fibrillation · Coronary Artery Disease · Cardiovascular Diseases, led by 7 companies.

Drug pageRanolazine: every studyMany companies study it; this page follows only the 25 they lead. All 85 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Mar 24, 200825 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciencesits history only180 open or runningphase 4since Mar 24, 2008Sep 8, 2004none ahead
Menarini Groupits history only20 open or runningphase 2since Feb 10, 2012Feb 10, 2012none ahead
Amit Malhotra, MDits history only10 open or runningphase 4since Jan 26, 2017Jan 26, 2017none ahead
Haisco Pharmaceutical Groupits history only10 open or runningphase 1since Jun 27, 2025Jun 27, 2025none ahead
Novartisits history only10 open or runningphase 2since Mar 21, 2012Mar 21, 2012none ahead
OBS Pakistan10 open or runningphase 4since Mar 15, 2018Mar 15, 2018none ahead
TSH Biopharmits history only10 open or runningno phasesince Jan 7, 2018Jan 7, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of OBS Pakistan only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 15, 2018First study: phase 4 study in Angina, StableFirst studyNCT03486561 · 2,000 enrolled

TargetBeta

SCN4A →SCN5A →read by rule
“Sodium channel protein type V alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
LidocaineruleKeenova Therapeuticsphase 463
LamotrigineruleGlaxoSmithKlinephase 461
Carbamazepinerulegrin-therapeutics-incphase 421
DronedaroneruleSanofiphase 418
chloroprocainerulesintetica-saphase 48
RiluzoleruleSanofiphase 46
PrilocaineruleHaisco Pharmaceutical Groupphase 42
CarticaineruleLaboratoires Theaphase 41
Ropivacainerulepainreform-ltdphase 317
QuinidineruleOtsukaphase 317
PhenytoinruleViatrisphase 310
rufinamideruleEisaiphase 37

Studies

The one study OBS Pakistan leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03486561Angina, Stable4UNKNOWNSep 30, 20182,000

How it is read

Names in the registry

  • “Ranolazine”, 24 entries
  • “Test formulation (Ranolazine extended-release tablets)”, 1 entry
  • “Reference formulation (Ranolazine extended-release tablets)”, 1 entry
  • “Ranolazine 500 mg”, 1 entry
  • “Ranolazine plus Metoprolol Combination”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.